Effect of the tyrosine kinase inhibitor nilotinib in patients with hypereosinophilic syndrome/chronic eosinophilic leukemia: analysis of the phase 2, open-label, single-arm A2101 study
暂无分享,去创建一个
M. Baccarani | H. Kantarjian | A. Reiter | F. Giles | P. Erben | A. Hochhaus | P. Coutre | Xiaolin Fan | S. Novick | T. McCulloch